SCHEMBL369533

SCHEMBL369533

CCC(O)c1nn(Cc2ccc(OC)cc2)cc1C(=O)C(Br)(CC)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 3/20 0.39
CACNA1H O95180 3/20 0.39
CACNA1I Q9P0X4 3/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 2/20 0.37
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
AADAT Q8N5Z0 1/20 0.36
KLKB1 P03952 3/20 0.35
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
HDAC1 Q13547 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
LDHA P00338 1/20 0.34
CHRM1 P11229 1/20 0.34
SNCA P37840 1/20 0.34
DGAT1 O75907 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370871 0.83 LDHA (0.42) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL369329 0.83 KMT2A (0.42) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL12482396 0.82 KMT2A (0.41) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL369532 0.79 KMT2A (0.37) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL368607 0.78 CACNA1G (0.41) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL370870 0.77 CACNA1G (0.40) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL370320 0.70 KMT2A (0.54) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL370457 0.69 KLKB1 (0.48) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL369065 0.69 KLKB1 (0.46) CACNA1GCACNA1HCACNA1IKMT2ANPC1
SCHEMBL6837432 0.69 KMT2A (0.41) CACNA1GCACNA1HCACNA1IKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 CACNA1G 353/4885CACNA1H 416/4885CACNA1I 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.